Why the study?
Can serum nitric oxide levels predict response to bevacizumab in patients with non-small cell lung cancer?
Can serum nitric oxide levels predict response to bevacizumab in patients with non-small cell lung cancer?
A decrease in serum nitric oxide levels after two courses of bevacizumab may serve as a predictive biomarker for improved progression-free survival in NSCLC patients.
Suggests early nitric oxide reduction may predict bevacizumab response in NSCLC; leaves open whether this.
BACKGROUND/AIM: Reportedly, hypertension tends to be associated with response to bevacizumab therapy, because bevacizumab suppresses vascular nitric oxide production. In this study we examined the predictive value of nitric oxide in bevacizumab-treated non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: ) was assayed by the Griess method. RESULTS: Serum nitric oxide levels were decreased after two courses of bevacizumab treatment in our responder group (p=0.02). According to the change in nitric oxide levels after the second course of treatment, median progression-free survival was 11.0 months in the group with decreased serum nitric oxide and 7.6 months in the group with increased serum nitric oxide (p=0.08). CONCLUSION: Serum nitric oxide levels could be a predictive biomarker for response to bevacizumab in NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Muto et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: